高敏心肌肌钙蛋白I检测的批间变异性及其临床影响
本研究评估了迈瑞高敏心肌肌钙蛋白I化学发光免疫分析法在急诊疑似心肌损伤患者中的分析性能和临床性能,并与Beckman Coulter Access和Abbott Architect方法进行比较。研究纳入400例急诊患者共823份血浆样本,重点关注试剂和校准品批间变异性。结果显示该检测法批间一致性优良(kappa 0.98),但不同检测平台间诊断一致性存在差异。
要点
- 迈瑞hs-cTnI检测批间一致性优良,偏差0.73%,kappa 0.98
- 与Architect诊断一致性(kappa 0.93)高于Access(kappa 0.77)
- 仍需持续监测试剂和校准品批号更换以确保分析一致性
核心结论
- 迈瑞hs-cTnI检测法展现出稳健的分析和临床性能,批间稳定性优良,但建议持续监测试剂和校准品批号变化。
研究设计与样本
- 研究纳入400例急诊疑似心肌损伤患者(AOUP 213例,ULSS7 187例),共823份锂肝素血浆样本,于基线、2小时及可用的第三时间点采集。
- 批间可比性在424份样本中使用两种试剂/校准品批号组合(R1/C1和R2/C2)进行评估,并在51份额外样本中用四种批号组合进一步探索。
主要发现
- 实验室内不精密度在2.45 ng/L处为2.03%,在4.76 ng/L处为2.25%。
- 在急诊离院患者中,迈瑞检测基线值超过第99百分位的比例(P1: 16.2%,P2: 15.1%)低于常规方法(P1: 26.8%,P2: 17.8%)。
- 与Architect的诊断一致性(Cohen's kappa 0.93)高于与Access的一致性(kappa 0.77)。
- R1/C1与R2/C2批间比较显示极好的一致性(偏差0.73%;kappa 0.98)。
临床怎么用
- 迈瑞hs-cTnI检测可用于急诊疑似心肌损伤的评估,但需注意不同检测平台间诊断一致性存在差异。
- 试剂或校准品批号更换时建议进行批间比对,以确保分析一致性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: High-sensitivity cardiac troponin I (hs-cTnI) assays are pivotal for diagnosing acute coronary syndromes and implementing accelerated rule-in/rule-out algorithms in the emergency department (ED). This study assessed the analytical and clinical performance of the Mindray hs-cTnI chemiluminescent immunoassay in comparison with the assays routinely adopted at the University Hospital of Padova (AOUP; Access, Beckman Coulter) and at Bassano Hospital (ULSS7; Architect, Abbott). Particular attention was given to reagent and calibrator lot-to-lot variability and its potential clinical impact. METHODS: The study included 400 ED patients with suspected myocardial injury (213 at AOUP [P1] and 187 at ULSS7 [P2]), yielding a total of 823 lithium-heparin plasma samples collected at baseline, 2 h, and, when available, at a third time point. Lot-to-lot comparability was examined in 424 samples using two reagent/calibrator lot combinations (R1/C1 and R2/C2) and further explored in 51 additional samples tested with four lot combinations. RESULTS: Within-laboratory imprecision was 2.03 % at 2.45 ng/L and 2.25 % at 4.76 ng/L. Among patients discharged from ED, the proportion of baseline values exceeding the 99th percentile was lower with the Mindray assay (P1: 16.2 %, P2: 15.1 %) compared with routine methods (P1: 26.8 %, P2: 17.8 %). Furthermore, diagnostic agreement was higher with Architect than with Access (Cohen's kappa 0.93 vs. 0.77). Lot-to-lot comparison demonstrated excellent concordance between R1/C1 and R2/C2 (bias 0.73 %; kappa 0.98). CONCLUSIONS: The evaluated assay demonstrated robust analytical and clinical performance, together with excellent lot-to-lot stability. Nevertheless, ongoing surveillance of reagent and calibrator lot changes remains advisable to ensure sustained analytical consistency and clinical reliability.
引用
- Pangrazzi E, Talli I, Cosma C, et al. Lot-to-lot variability of a high-sensitivity cardiac troponin I assay: clinical implications. Clin Chem Lab Med. 2026. PMID: 42117499. doi:10.1515/cclm-2026-0315
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。